ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Acute coronary syndrome,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
1,2,Cardiotoxicity,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
1,3,Left ventricular dysfunction,Myocardial disorders NEC,Myocardial disorders,Card,N
1,4,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
2,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
2,2,Headache,Headaches NEC,Headaches,Nerv,N
2,3,Hepatic pain,Hepatobiliary signs and symptoms,Hepatic and hepatobiliary disorders,Hepat,N
2,4,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
2,5,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
2,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2,7,Pancreatic neuroendocrine tumour,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
2,8,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2,9,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
3,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
3,2,Drug dependence,Substance related and addictive disorders,Psychiatric disorders NEC,Psych,N
3,3,Encephalitis,Central nervous system and spinal infections,Infections - pathogen unspecified,Infec,N
3,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
3,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
3,6,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
3,7,Liver abscess,Hepatobiliary and spleen infections,Infections - pathogen unspecified,Infec,N
3,8,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
3,9,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
3,10,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
3,11,Pancreatic neuroendocrine tumour,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
3,12,Performance status decreased,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3,13,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
3,14,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
4,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4,3,Dry eye,Lacrimation disorders,Eye disorders NEC,Eye,N
4,4,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
4,5,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
4,6,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
4,7,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
4,8,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
4,9,Lacrimation increased,Lacrimation disorders,Eye disorders NEC,Eye,N
4,10,Liver disorder,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
4,11,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
4,12,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
4,13,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
4,14,Pancreatic neuroendocrine tumour,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
4,15,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
4,16,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
4,17,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
4,18,Tumour necrosis,Oncologic complications and emergencies,Neoplasm related morbidities,Neopl,N
